Test two supplements for long fatigue from EBV infection
Part of Infections clinical trials.
This trial studies whether two products (2LEBV® and 2LXFS®) can improve ongoing fatigue in people who have evidence of an Epstein-Barr virus (EBV) infection. It aims to see if treatment helps reduce multiple related symptoms over follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 12 or older
- Have fatigue lasting at least 1 month
- Have EBV blood test positive for IgG and/or IgM
- Have at least two additional symptoms along with fatigue
- Be willing to do study blood tests (serology and lymphocyte typing) and follow the schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks health outcomes over time in people who have a high level of the EBV virus in their blood. It may help researchers understand what happens in chronic (long-lasting) EBV infection and which outcomes to watch for.
This study looks at why fatigue doesn't go away after an EBV infection. It tests people who are early in their illness to understand the mechanisms.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Hear when a new EBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.